Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 36 · MACD below its signal · 8% above its 52-week low
| 7.98 | 52-week high | +161.31% |
| 5.10 | Previous month high | +66.94% |
| 3.54 | Previous week high | +15.88% |
| 3.46 | R3 (classic) | +13.26% |
| 3.32 | R2 (classic) | +8.67% |
| 3.21 | R1 (classic) | +5.24% |
| 3.18 | Previous day high | +4.09% |
| 3.15 | Previous week low | +3.11% |
| 3.11 | Previous month low | +1.64% |
| 3.07 | Pivot | +0.65% |
| 3.06 | Price now | |
| 2.97 | S1 (classic) | −2.78% |
| 2.93 | Previous day low | −3.93% |
| 2.83 | S2 (classic) | −7.36% |
| 2.82 | 52-week low | −7.69% |
| 2.72 | S3 (classic) | −10.80% |
None of the 29 investors followed here reported a position in IVA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IVA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for IVA.
TimeframesDown on the daily and weekly, mixed on the hourly and monthly.
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 32.5 | 5.4 | -14.5 | -7.6 | -3.9 | -23.3 | 18.5 | 4.5 | -21.2 | -17.2 | −34.3% | ||
| 2025 | 13.4 | 30.7 | -7.3 | 25.9 | -8.4 | -5.9 | 4.9 | 85.1 | -6.5 | -25.7 | -1.2 | 9.4 | +117.3% |
| 2024 | -15.9 | -4.7 | 0.0 | -15.2 | 19.5 | -18.5 | -23.4 | -1.1 | -17.7 | 42.6 | -0.4 | -19.2 | −52.6% |
| 2023 | 39.5 | -17.9 | -28.8 | -25.3 | 45.0 | 2.4 | 1.2 | -9.5 | 13.5 | -10.0 | 11.1 | 7.5 | +1.3% |
| 2022 | -11.6 | 10.9 | -14.9 | -17.5 | -4.0 | -37.1 | -15.4 | -6.2 | -12.6 | 16.5 | -8.8 | 6.8 | −67.3% |
| 2021 | 1.4 | 2.0 | -2.0 | -8.7 | 1.8 | -0.2 | -1.4 | -1.8 | 7.3 | 10.5 | -15.0 | 2.7 | −5.8% |
| 2020 | 23.4 | -6.0 | 9.1 | -0.8 | 13.3 | +42.3% |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Buy / hold / sell counts